Pharmacotherapy is an important component of treatment for children and adolescents with bipolar disorder. The body of evidence supporting safe and effective treatments in this population is growing. Available data provide information on the risks and benefits of pharmacologic agents used for acute manic, mixed, and depressive episodes as well as for maintenance treatment. Lithium, anticonvulsants, and antipsychotics comprise the armamentarium for treating pediatric bipolar disorder. When selecting treatment, clinicians must consider the efficacy and side effect profile of potential pharmacotherapies, as well as the patient’s history, including the presence of comorbidities, in order to develop a treatment plan that will ensure optimal outcomes.
The Journal of Clinical Psychiatry
Supplement Article September 15, 2016
Evidence-Based Pharmacologic Treatment of Pediatric Bipolar Disorder
J Clin Psychiatry 2016;77(suppl E1):e02
Article Abstract
Vol 87 • 2026 • Number 1
Read the Current Issue
ASCP Corner
Rethinking Amisulpride: Could N-Methylation Result in a New and Even Better Antipsychotic?
Original Research
How Many Criteria Should be Required to Define the DSM-5 Mixed Features Specifier in Depressed Patients?
Meta-Analysis
Effectiveness of Peer-Administered Interventions for Perinatal Depression or Anxiety
Original Research
Innovation in Psychiatric Drug Development: A Quantitative Analysis of FDA-Approved Psychiatric Drugs, 2012–2024
Brief Report
Exercise Reduces Dysphoria in Clinical High-Risk for Psychosis: A Randomized Controlled Trial
Clinical and Practical Psychopharmacology